Amicus Therapeutics
Cranbury, US · Delaware corporation · 4 known investors
Amicus is a wholly owned subsidiary of BioMarin Pharmaceutical Inc., a global rare disease biotechnology company that develops medicines for people with genetically defined conditions.
Founders & leadership
DQ
Daphne QuimiExecutive Officer
CA
Craig A. WheelerDirector
TW
Ted W. LoveDirector
JC
John CrowleyExecutive Officer, Director
WD
William D. Baird, IIIExecutive Officer
MG
Margaret G. McGlynnDirector
DJ
Donald J. Hayden, Jr.Director
SB
Sol BarerDirector
GS
Glen SblendorioDirector
RE
Robert EssnerDirector
MR
Michael RaabDirector
Investors · 4
Reported raises · per SEC filings
Form D private placements▶$30MraisedOct 2023 · 2 investors · BiotechnologyRule 506(b)
▶$30MraisedOct 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John F CrowleyDirector
- David ClarkExecutive Officer
- Eiry W Roberts, M.D.Director
- Ellen S. RosenbergExecutive Officer
- Margaret G. McGlynnDirector
- Craig A WheelerDirector
- Michael A KellyDirector
- Bradley CampbellExecutive Officer, Director
- Michael G RaabDirector
- Simon HarfordExecutive Officer
- Glenn P SblendorioDirector
- Burke W WhitmanDirector
- Lynn D BleilDirector
- Jeffrey P. Castelli, Ph.D.Executive Officer
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$199.9MraisedOct 2021 · 9 investors · BiotechnologyRule 506(b)
▶$199.9MraisedOct 2021 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John F. CrowleyExecutive Officer, Director
- Michael A. KellyDirector
- Bradley L. CampbellExecutive Officer, Director
- Michael RaabDirector
- Samantha ProutExecutive Officer
- Margaret G. McGlynnDirector
- Burke W. WhitmanDirector
- Eiry L. RobertsDirector
- Daphne QuimiExecutive Officer
- Craig A. WheelerDirector
- Lynn D. BleilDirector
- Robert EssnerDirector
- Ellen S. RosenbergExecutive Officer
- Glenn P. SblendorioDirector
- David M. ClarkExecutive Officer
- Offering amount
- $199.9M
- Amount sold
- $199.9M
- Minimum investment
- $2.1M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.7MraisedJul 2016 · 18 investors · BiotechnologyRule 506(b)
▶$4.7MraisedJul 2016 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daphne QuimiExecutive Officer
- Craig A. WheelerDirector
- Ted W. LoveDirector
- John CrowleyExecutive Officer, Director
- William D. Baird, IIIExecutive Officer
- Margaret G. McGlynnDirector
- Donald J. Hayden, Jr.Director
- Sol BarerDirector
- Glen SblendorioDirector
- Robert EssnerDirector
- Michael RaabDirector
- Offering amount
- $4.7M
- Amount sold
- $4.7M
- Sales commissions
- $5K
- Finders' fees
- $5K
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.